| Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease L Jostins, S Ripke, RK Weersma, RH Duerr, DP McGovern, KY Hui, ... Nature 491 (7422), 119-124, 2012 | 5201 | 2012 |
| Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci A Franke, DPB McGovern, JC Barrett, K Wang, GL Radford-Smith, ... Nature genetics 42 (12), 1118-1125, 2010 | 3147 | 2010 |
| Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target L Peyrin-Biroulet, W Sandborn, BE Sands, W Reinisch, W Bemelman, ... Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 1836 | 2015 |
| Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 CA Anderson, G Boucher, CW Lees, A Franke, M D'Amato, KD Taylor, ... Nature genetics 43 (3), 246-252, 2011 | 1717 | 2011 |
| Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study I Cleynen, G Boucher, L Jostins, LP Schumm, S Zeissig, T Ahmad, ... The Lancet 387 (10014), 156-167, 2016 | 846 | 2016 |
| Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry EJ Brenner, RC Ungaro, RB Gearry, GG Kaplan, M Kissous-Hunt, ... Gastroenterology 159 (2), 481-491. e3, 2020 | 731 | 2020 |
| World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010 CN Bernstein, M Fried, JH Krabshuis, H Cohen, R Eliakim, S Fedail, ... Inflammatory bowel diseases 16 (1), 112-124, 2010 | 696 | 2010 |
| International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease L Jostins, S Ripke, RK Weersma, RH Duerr, DP McGovern, KY Hui, ... Nature 491 (7422), 119-124, 2012 | 627 | 2012 |
| Crohn's disease management after intestinal resection: a randomised trial P De Cruz, MA Kamm, AL Hamilton, KJ Ritchie, EO Krejany, A Gorelik, ... The Lancet 385 (9976), 1406-1417, 2015 | 626 | 2015 |
| Dietary poorly absorbed, short‐chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon JS Barrett, RB Gearry, JG Muir, PM Irving, R Rose, O Rosella, ML Haines, ... Alimentary pharmacology & therapeutics 31 (8), 874-882, 2010 | 519 | 2010 |
| Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: a meta-analysis R Ungaro, CN Bernstein, R Gearry, A Hviid, KL Kolho, MP Kronman, ... Official journal of the American College of Gastroenterology| ACG 109 (11 …, 2014 | 484 | 2014 |
| The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study RH De Roest, BR Dobbs, BA Chapman, B Batman, LA O'brien, JA Leeper, ... International journal of clinical practice 67 (9), 895-903, 2013 | 450 | 2013 |
| Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study RB Gearry, PM Irving, JS Barrett, DM Nathan, SJ Shepherd, PR Gibson Journal of Crohn's and Colitis 3 (1), 8-14, 2009 | 406 | 2009 |
| Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection M Julsgaard, LA Christensen, PR Gibson, RB Gearry, J Fallingborg, ... Gastroenterology 151 (1), 110-119, 2016 | 352 | 2016 |
| High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study RB Gearry, A Richardson, CMA Frampton, JA Collett, MJ Burt, ... Inflammatory bowel diseases 12 (10), 936-943, 2006 | 346 | 2006 |
| Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection M Regueiro, BG Feagan, B Zou, J Johanns, MA Blank, M Chevrier, ... Gastroenterology 150 (7), 1568-1578, 2016 | 326 | 2016 |
| Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery EK Wright, MA Kamm, P De Cruz, AL Hamilton, KJ Ritchie, EO Krejany, ... Gastroenterology 148 (5), 938-947. e1, 2015 | 326 | 2015 |
| Population‐based cases control study of inflammatory bowel disease risk factors RB Gearry, AK Richardson, CM Frampton, AJ Dodgshun, ML Barclay Journal of gastroenterology and hepatology 25 (2), 325-333, 2010 | 298 | 2010 |
| Effect of IBD medications on COVID-19 outcomes: results from an international registry RC Ungaro, EJ Brenner, RB Gearry, GG Kaplan, M Kissous-Hunt, ... Gut 70 (4), 725-732, 2021 | 296 | 2021 |
| Azathioprine and 6‐mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease RB Gearry, ML Barclay Journal of gastroenterology and hepatology 20 (8), 1149-1157, 2005 | 287 | 2005 |
